by Richard Daverman, PhD
March 26, 2014 -- Jiangsu Nhwa Pharma will spend $64 million to build an API manufacturing facility in Xuzhou. The plant, which will conform to US and European standards, will make central nervous system APIs for Nhwa’s own use and for sale to other companies, including export. The planned capacity of the new facility is 200 tons annually. It is expected to produce revenues of $64 million and profits of $15 million. More details....
Help employers find you! Check out all the jobs and post your resume.
